Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) EBIT: 2009-2025

Historic EBIT for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to -$166.8 million.

  • Cytokinetics' EBIT fell 18.43% to -$166.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$572.9 million, marking a year-over-year decrease of 9.21%. This contributed to the annual value of -$536.2 million for FY2024, which is 8.07% down from last year.
  • Per Cytokinetics' latest filing, its EBIT stood at -$166.8 million for Q3 2025, which was down 49.55% from -$111.5 million recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' EBIT registered a high of -$10.9 million during Q2 2022, and its lowest value of -$166.8 million during Q3 2025.
  • For the 3-year period, Cytokinetics' EBIT averaged around -$133.3 million, with its median value being -$127.4 million (2023).
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 1,434.90% in 2021, then soared by 80.16% in 2022.
  • Over the past 5 years, Cytokinetics' EBIT (Quarterly) stood at -$21.7 million in 2021, then slumped by 485.28% to -$127.0 million in 2022, then fell by 0.31% to -$127.4 million in 2023, then decreased by 9.12% to -$139.0 million in 2024, then fell by 18.43% to -$166.8 million in 2025.
  • Its EBIT stands at -$166.8 million for Q3 2025, versus -$111.5 million for Q2 2025 and -$155.6 million for Q1 2025.